Ethosuximide
Ethosuximide is an anticonvulsant specifically indicated for the control of absence (petit mal) epilepsy. It is considered the drug of choice for absence seizures due to its high efficacy and relatively favorable side effect profile compared to other anticonvulsants for this indication.
Clinical Overview
Primary Clinical Applications
Ethosuximide is the first-line treatment for typical absence seizures, particularly effective for the characteristic 3-Hz spike-and-wave discharges seen in childhood absence epilepsy. It is not effective for other seizure types and may actually worsen tonic-clonic seizures if used as monotherapy.
Mechanism and Clinical Benefits
Ethosuximide works by blocking T-type calcium channels in thalamic neurons, which are crucial for generating the rhythmic spike-and-wave discharges characteristic of absence seizures. This selective mechanism makes it highly effective for absence epilepsy while having minimal effects on other seizure types.
Clinical Considerations
The medication has a long half-life allowing for twice-daily dosing in most patients. Therapeutic drug monitoring may be helpful to optimize dosing, with target serum levels of 40-100 mcg/mL. Ethosuximide is generally well-tolerated but requires gradual dose titration to minimize gastrointestinal side effects.
Key Clinical Points
Absence seizures only
Ethosuximide blocks T-type calcium channels in thalamic neurons, which is precisely why it works for the 3-Hz spike-and-wave discharges of absence epilepsy and does nothing for other seizure types.
May worsen tonic-clonic seizures as monotherapy
In patients with mixed seizure disorders, ethosuximide alone can exacerbate generalised tonic-clonic seizures. Concurrent broad-spectrum cover is needed where both types are present.
Target serum levels of 40 to 100 mcg/mL
Therapeutic drug monitoring is well established and useful, particularly given interactions: valproate and isoniazid raise levels while phenytoin and carbamazepine lower them.
Blood dyscrasias and drug-induced lupus
Aplastic anaemia and agranulocytosis warrant periodic full blood count monitoring, and systemic lupus erythematosus has been reported. Contraindicated where there is a history of blood dyscrasias.
Taper to avoid withdrawal seizures
Abrupt discontinuation can precipitate absence status. Gradual titration on the way up also limits the nausea and abdominal pain that are the most common early adverse effects.
Prescribing Information
Dosing & Administration
Absence Epilepsy – Children (3-6 years):
- Initial: 250 mg once daily
- Titration: Increase by 250 mg every 4-7 days as needed
- Maintenance: 20 mg/kg/day
Children (≥6 years) and Adults:
- Initial: 500 mg daily (250 mg twice daily)
- Titration: Increase by 250 mg every 4-7 days
- Maintenance: 20-40 mg/kg/day (maximum 1.5 g/day)
- Target serum level: 40-100 mcg/mL
Administration:
- May take with food to reduce GI upset
- Divide daily dose into 2-3 administrations
- Consistent timing with meals
Indications
- Control of absence (petit mal) epilepsy
- First-line treatment for typical absence seizures
Contraindications
- Hypersensitivity to ethosuximide or any component
- History of blood dyscrasias
Warnings & Precautions
- Blood dyscrasias: Monitor CBC periodically, especially with symptoms
- Suicidal thoughts: Monitor for behavioral changes
- Systemic lupus erythematosus: Rare but serious risk
- Skin reactions: Stevens-Johnson syndrome reported rarely
- Hepatic effects: Monitor liver function periodically
- Withdrawal seizures: Taper gradually when discontinuing
Drug Interactions
- Valproic acid: May increase ethosuximide levels
- Phenytoin: May decrease ethosuximide levels
- Carbamazepine: May decrease ethosuximide levels
- Isoniazid: May increase ethosuximide levels
Adverse Reactions
Common (>10%):
- Nausea, vomiting, anorexia, abdominal pain
- Drowsiness, dizziness, headache
Serious but Rare:
- Blood dyscrasias (aplastic anemia, agranulocytosis)
- Stevens-Johnson syndrome, systemic lupus erythematosus
Special Populations
- Renal Impairment: Use caution, may require dose adjustment
- Hepatic Impairment: Use caution, monitor liver function
- Pregnancy: Category C – use only if benefits outweigh risks
- Monitoring: CBC, liver function, therapeutic drug levels
Frequently Asked Questions
What is Ethosuximide used for?
Ethosuximide is an anticonvulsant specifically indicated for the control of absence (petit mal) epilepsy. It is considered the drug of choice for absence seizures due to its high efficacy and relatively favorable side effect profile compared to other anticonvulsants for this indication.
What class of drug is Ethosuximide?
Ethosuximide is classified as: Anticonvulsant.
Absence seizures only?
Ethosuximide blocks T-type calcium channels in thalamic neurons, which is precisely why it works for the 3-Hz spike-and-wave discharges of absence epilepsy and does nothing for other seizure types.
May worsen tonic-clonic seizures as monotherapy?
In patients with mixed seizure disorders, ethosuximide alone can exacerbate generalised tonic-clonic seizures. Concurrent broad-spectrum cover is needed where both types are present.
Target serum levels of 40 to 100 mcg/mL?
Therapeutic drug monitoring is well established and useful, particularly given interactions: valproate and isoniazid raise levels while phenytoin and carbamazepine lower them.
Blood dyscrasias and drug-induced lupus?
Aplastic anaemia and agranulocytosis warrant periodic full blood count monitoring, and systemic lupus erythematosus has been reported. Contraindicated where there is a history of blood dyscrasias.
Source: FDA prescribing information (DailyMed)